|
Eine Ebene nach oben |
Gruppiert nach:
Dokumententyp
| Veröffentlichungsdatum
Springe zu: Zeitschriftenartikel
Anzahl der Publikationen: 26
Zeitschriftenartikel
Weiss, L.; Heinrich, K.; Zhang, D.; Dorman, K.; Rühlmann, K.; Hasselmann, K.; Klauschen, F.; Kumbrink, J.; Jung, A.; Rudelius, M.; Mock, A.; Ormanns, Steffen 
ORCID: https://orcid.org/0000-0002-0754-9034; Kunz, W. G.; Roessler, D.; Beyer, G.; Corradini, S.; Heinzerling, L.; Haas, M.; Bergwelt-Baildon, Michael von ORCID: https://orcid.org/0000-0002-1952-052X; Boeck, S.; Heinemann, Volker ORCID: https://orcid.org/0000-0002-1349-3321 und Westphalen, C. B. ORCID: https://orcid.org/0000-0002-5310-3754
(2023):
Cancer of unknown primary (CUP) through the lens of precision oncology: a single institution perspective.
In: Journal of Cancer Research and Clinical Oncology, Bd. 149, Nr. 11: S. 8225-8234
[PDF, 623kB]
ORCID: https://orcid.org/0000-0002-0754-9034; Kunz, W. G.; Roessler, D.; Beyer, G.; Corradini, S.; Heinzerling, L.; Haas, M.; Bergwelt-Baildon, Michael von ORCID: https://orcid.org/0000-0002-1952-052X; Boeck, S.; Heinemann, Volker ORCID: https://orcid.org/0000-0002-1349-3321 und Westphalen, C. B. ORCID: https://orcid.org/0000-0002-5310-3754
(2023):
Cancer of unknown primary (CUP) through the lens of precision oncology: a single institution perspective.
In: Journal of Cancer Research and Clinical Oncology, Bd. 149, Nr. 11: S. 8225-8234
[PDF, 623kB]
Kruger, S. F.; Lohneis, A.; Abendroth, A.; Berger, A. W.; Ettrich, T. J.; Waidmann, O.; Kapp, M.; Steiner, B.; Kumbrink, J.; Reischer, A.; Haas, M.; Westphalen, C. B.; Zhang, D.; Miller-Phillips, L.; Burger, P. J.; Kobold, S.; Werner, J.; Subklewe, M.; Bergwelt-Baildon, M. von; Kunzmann, V.; Seufferlein, T.; Siveke, J. T.; Sinn, M.; Heinemann, V.; Ormanns, S. und Boeck, S.
(2022):
Prognosis and tumor biology of pancreatic cancer patients with isolated lung metastases: translational results from the German multicenter AIO-YMO-PAK-0515 study.
In: ESMO Open, Bd. 7, Nr. 1, 100388
Sams, L.; Kruger, S.; Heinemann, V.; Bararia, D.; Häbe, S.; Alig, S.; Haas, M.; Zhang, D.; Westphalen, C. B.; Ormanns, S.; Metzger, P.; Werner, J.; Weigert, O.; von Bergwelt-Baildon, M.; Rataj, F.; Kobold, S. und Böck, S.
(2021):
Alterations in regulatory T cells and immune checkpoint molecules in pancreatic cancer patients receiving FOLFIRINOX or gemcitabine plus nab-paclitaxel.
In: Clinical & Translational Oncology, Bd. 23, Nr. 11: S. 2394-2401
Haas, M.; Waldschmidt, D. T.; Stahl, M.; Reinacher-Schick, A.; Freiberg-Richter, J.; Fischer von Weikersthal, L.; Kaiser, F.; Kanzler, S.; Frickhofen, N.; Seufferlein, T.; Dechow, T.; Mahlberg, R.; Malfertheiner, P.; Illerhaus, G.; Kubicka, S.; Abdul-Ahad, A.; Snijder, R.; Kruger, S.; Westphalen, C. B.; Held, S.; Bergwelt-Baildon, M. von; Boeck, S. und Heinemann, V.
(2021):
Afatinib plus gemcitabine versus gemcitabine alone as first-line treatment of metastatic pancreatic cancer: The randomised, open-label phase II ACCEPT study of the Arbeitsgemeinschaft Internistische Onkologie with an integrated analysis of the 'burden of therapy' method.
In: European Journal of Cancer, Bd. 146: S. 95-106
Sams, L.; Kruger, S.; Heinemann, V.; Bararia, D.; Haebe, S.; Alig, S.; Haas, M.; Zhang, D.; Westphalen, C. B.; Ormanns, S.; Metzger, P.; Werner, J.; Weigert, O.; von Bergwelt-Baildon, M.; Rataj, F.; Kobold, S. und Boeck, S.
(2021):
Alterations in regulatory T cells and immune checkpoint molecules in pancreatic cancer patients receiving FOLFIRINOX or gemcitabine plus nab-paclitaxel.
In: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
[PDF, 1MB]
Westphalen, C. B.; Preinfalk, A.; Krüger, S.; Haas, M.; Renz, B. W.; Riener, M.-O.; Weber, A.; Kirchner, T.; Werner, J.; Heinemann, V; Bergwelt-Baildon, M. von; Baba, H. A.; Siveke, J. T.; Ormanns, S. und Böck, S.
(2019):
Neurotrophic tropomyosin receptor kinase (NTRK) and nerve growth factor (NGF) are not expressed in Caucasian patients with biliary tract cancers: pooled data from three independent cohorts.
In: Clinical & Translational Oncology, Bd. 21, Nr. 8: S. 1108-1111
Pallmann, S.; Steflova (nee Svobodova), J.; Haas, M.; Lamour, S.; Henss, A. und Trapp, O.
(2018):
Schreibersite: an effective catalyst in the formose reaction network.
In: New Journal of Physics, Bd. 20, 55003
[PDF, 1MB]
Haas, M.; Siveke, J. T.; Schenk, M.; Lerch, M. M.; Caca, K.; Freiberg-Richter, J.; Fischer von Weikersthal, L.; Kullmann, F.; Reinacher-Schick, A.; Fuchs, M.; Kanzler, S.; Kunzmann, V.; Ettrich, T. J.; Kruger, S.; Westphalen, C. B.; Held, S.; Heinemann, V. und Böck, S.
(2018):
Efficacy of gemcitabine plus erlotinib in rash-positive patients with metastatic pancreatic cancer selected according to eligibility for FOLFIRINOX: A prospective phase II study of the 'Arbeitsgemeinschaft Internistische Onkologie'.
In: European Journal of Cancer, Bd. 94: S. 95-103
Krüger, S.; Heinemann, V.; Ross, C.; Diehl, F.; Nagel, D.; Ormanns, S.; Liebmann, S.; Prinz-Bravin, I.; Westphalen, C. B.; Haas, M.; Jung, A.; Kirchner, T.; Bergwelt-Baildon, M. von; Böck, S. und Holdenrieder, S.
(2018):
Repeated (mut)KRAS ctDNA measurements represent a novel and promising tool for early response prediction and therapy monitoring in advanced pancreatic cancer.
In: Annals of Oncology, Bd. 29, Nr. 12: S. 2348-2355
Böck, S.; Mehraein, Y.; Ormanns, S.; Kruger, S.; Westphalen, C. Benedikt; Haas, M.; Jung, A.; Kirchner, T. und Heinemann, V.
(2017):
Mismatch-repair-deficient metastatic pancreatic ductal adenocarcinoma with a germline PALB2 mutation: unusual genetics, unusual clinical course.
In: Annals of Oncology, Bd. 28, Nr. 2: S. 438-439
Haas, M.; Böck, S.; Siveke, J. T.; Schenk, M.; Lerch, M.; Caca, K.; Freiberg-Richter, J.; Fischer von Weikersthal, L.; Kullmann, F.; Reinacher-Schick, A.; Fuchs, M.; Ettrich, T. J.; Kanzler, S.; Kunzmann, V.; Kruger, S.; Westphalen, C. B.; Held, S. und Heinemann, V.
(2017):
Efficacy of gemcitabine plus erlotinib for rash-positive metastatic pancreatic cancer patients eligible for treatment with FOLFIRINOX - a prospective phase II trial of the "Arbeitsgemeinschaft Internistische Onkologie" - AIO.
In: Oncology Research and Treatment, Bd. 40: S. 207-208
Kruger, S.; Ormanns, S.; Rösgen, V.; Legenstein, M.-L.; Haas, M.; Westphalen, C. B.; Düwell, P.; Schnurr, M.; Heinemann, V.; Kirchner, T. und Böck, S.
(2017):
IDO1 expression as biomarker in erlotinib-treated patients with advanced pancreatic cancer: translational results from the AIO-PK0104 phase III trial.
In: Oncology Research and Treatment, Bd. 40: S. 235
Schwandt, P.; Liepold, E.; Heinzel-Gutenbrunner, M.; Bertsch, T. und Haas, M.
(2016):
Sustained nutritional counseling improves dietary intake in parents and their children over 5 years: The pep family heart study.
In: Atherosclerosis, Bd. 252, E89-E90
Michl, M.; Haug, A. R.; Jakobs, T. F.; Paprottka, P.; Hoffmann, R. T.; Bartenstein, P.; Boeck, S.; Haas, M.; Laubender, Rüdiger P. und Heinemann, V.
(2014):
Radioembolization with Yttrium-90 Microspheres (SIRT) in Pancreatic Cancer Patients with Liver Metastases: Efficacy, Safety and Prognostic Factors.
In: Oncology, Bd. 86, Nr. 1: S. 24-32
Michl, M.; Haug, A. R.; Jakobs, T. F.; Paprottka, Philipp M.; Hoffmann, R.-T.; Bartenstein, P.; Boeck, S.; Haas, M.; Laubender, R. P. und Heinemann, V.
(2014):
Radioembolization with Yttrium-90 microspheres (SIRT) in pancreatic cancer patients with liver metastases: Efficacy, safety and prognostic factors.
In: Oncology, Bd. 86, Nr. 1: S. 24-32
[PDF, 265kB]
Boeck, S.; Ormanns, S.; Haas, M.; Bachmann, S.; Laubender, Rüdiger P.; Siveke, J. T.; Jung, A.; Kirchner, T. und Heinemann, V.
(2014):
Translational research in pancreatic cancer: KRAS and beyond.
In: Pancreas, Bd. 43, Nr. 1: S. 150-152
Haas, M.; Heinemann, V.; Kullmann, F.; Laubender, Rüdiger P.; Klose, C.; Bruns, C. J.; Holdenrieder, S.; Modest, D. P.; Schulz, C. und Boeck, S.
(2013):
Prognostic value of CA 19-9, CEA, CRP, LDH and bilirubin levels in locally advanced and metastatic pancreatic cancer: results from a multicenter, pooled analysis of patients receiving palliative chemotherapy.
In: Journal of Cancer Research and Clinical Oncology, Bd. 139, Nr. 4: S. 681-689
Giessen, C.; Laubender, Rüdiger P.; Fischer von Weikersthal, L.; Schalhorn, A.; Modest, D. P.; Stintzing, S.; Haas, M.; Mansmann, Ulrich und Heinemann, V.
(2013):
Early tumor shrinkage in metastatic colorectal cancer: Retrospective analysis from an irinotecan-based randomized first-line trial.
In: Cancer Science, Bd. 104, Nr. 6: S. 718-724
Boeck, S.; Jung, A.; Laubender, Rüdiger P.; Neumann, J.; Egg, R.; Goritschan, C.; Ormanns, S.; Haas, M.; Modest, D. P.; Kirchner, T. und Heinemann, V.
(2013):
KRAS mutation status is not predictive for objective response to anti-EGFR treatment with erlotinib in patients with advanced pancreatic cancer.
In: Journal of Gastroenterology, Bd. 48, Nr. 4: S. 544-548
Zeiss, K.; Parhofer, K. G.; Heinemann, V.; Haas, M.; Laubender, Rüdiger P.; Holdenrieder, S.; Schulz, C. und Boeck, S.
(2013):
Glucose and lipid metabolism in patients with advanced pancreatic cancer receiving palliative chemotherapy.
In: Anticancer Research, Bd. 33, Nr. 1: S. 287-292
Modest, D. P.; Laubender, Rüdiger P.; Stintzing, S.; Giessen, C.; Schulz, C.; Haas, M.; Mansmann, Ulrich und Heinemann, V.
(2013):
Early tumor shrinkage in patients with metastatic colorectal cancer receiving first-line treatment with cetuximab combined with either CAPIRI or CAPOX: An analysis of the German AIO KRK 0104 trial.
In: Acta Oncologica, Bd. 52, Nr. 5: S. 956-962
Haas, M.; Laubender, Rüdiger P.; Klose, C.; Schulz, C.; Mansmann, Ulrich; Boeck, S. und Heinemann, V.
(2012):
External Validation of 2 Prognostic Indices for Patients With Advanced Pancreatic Cancer Treated With First-line Therapy.
In: Pancreas, Bd. 41, Nr. 5: S. 738-744
Modest, D. P.; Jung, A.; Moosmann, N.; Laubender, Rüdiger P.; Giessen, C.; Schulz, C.; Haas, M.; Neumann, J.; Boeck, S.; Kirchner, T.; Heinemann, V. und Stintzing, S.
(2012):
The influence of KRAS- and BRAF-mutations on the efficacy of cetuximab-based 1st-line therapy of metastatic colorectal cancer: An analysis of the AIO KRK-0104 -trial.
In: International Journal of Cancer, Bd. 131, Nr. 4: S. 980-986
Modest, D. P.; Stintzing, S.; Laubender, Rüdiger P.; Neumann, J.; Jung, A.; Giessen, C.; Haas, M.; Aubele, P.; Schulz, C.; Boeck, S.; Stemmler, H. J.; Kirchner, T. und Heinemann, V.
(2011):
Clinical characterization of patients with metastatic colorectal cancer depending on the KRAS status.
In: Anticancer Drugs, Bd. 22, Nr. 9: S. 913-918
Haas, M.; Laubender, Rüdiger P.; Stieber, P.; Holdenrieder, S.; Bruns, C. J.; Wilkowski, R.; Mansmann, Ulrich; Heinemann, V. und Boeck, S.
(2010):
Prognostic relevance of CA 19-9, CEA, CRP, and LDH kinetics in patients treated with palliative second-line therapy for advanced pancreatic cancer.
In: Tumor Biology, Bd. 31, Nr. 4: S. 351-357
Boeck, S.; Haas, M.; Laubender, Rüdiger P.; Kullmann, F.; Klose, C.; Bruns, C. J.; Wilkowski, R.; Stieber, P.; Holdenrieder, S.; Buchner, Hannes; Mansmann, Ulrich und Heinemann, V.
(2010):
Application of a time-varying covariate model to the analysis of CA 19-9 as serum biomarker in patients with advanced pancreatic cancer.
In: Clinical Cancer Research, Bd. 16, Nr. 3: S. 986-994